Evaluation of serum CCL18 as a potential biomarker for ovarian cancer

Early detection and differentiation diagnosis of a pelvic mass (PM) is crucial in improving the prognosis of patients with epithelial ovarian cancer (EOC). C-C motif chemokine ligand 18 (CCL18) was reported as a chemokine-mediated tumor-related inflammation that can be detected in serum and may corr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer biomarkers : section A of Disease markers 2017-12, Vol.21 (1), p.97-104
Hauptverfasser: Yuan, Linjing, Wan, Jianxin, Huang, Chumei, Liang, Jingjing, Liu, Min, Yue, Caifeng, Li, Laisheng
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 104
container_issue 1
container_start_page 97
container_title Cancer biomarkers : section A of Disease markers
container_volume 21
creator Yuan, Linjing
Wan, Jianxin
Huang, Chumei
Liang, Jingjing
Liu, Min
Yue, Caifeng
Li, Laisheng
description Early detection and differentiation diagnosis of a pelvic mass (PM) is crucial in improving the prognosis of patients with epithelial ovarian cancer (EOC). C-C motif chemokine ligand 18 (CCL18) was reported as a chemokine-mediated tumor-related inflammation that can be detected in serum and may correlate with cancer patients' prognosis. We performed this study to investigate the relationship between CCL18 levels and clinical characteristics of EOC patients, and to explore their diagnostic and prognostic values. CCL18 serum concentrations were detected by ELISA in 187 patients with EOC, 126 patients with benign PMs, and 118 healthy controls. CCL18 serum levels were analyzed in the context of patients' clinicopathological information, and ROC analyses were performed to determine the effect of CCL18 on distinguishing benign and malignant PMs. The ability of CCL18 to serve as an EOC biomarker was compared with CA125. Further survival analyses were carried out to assess the prognostic value of CCL18 in EOC patients. Mean serum CCL18 levels were elevated in benign PM patients and were even higher in EOC patients than in healthy controls; furthermore, high CCL18 expression was associated with worse International Federation of Gynecology and Obstetrics (FIGO) staging and predicted a poorer survival of the patient. When compared with CA125, although the sensitivity and negative predictive values (NPV) of serum CCL18 were lower, its specificity and positive predictive values (PPV) were higher. Serum CCL18 was elevated in patients with EOC and could serve as a new tumor biomarker, which also predicted a poor survival of the patient.
doi_str_mv 10.3233/CBM-170305
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1952107950</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1952107950</sourcerecordid><originalsourceid>FETCH-LOGICAL-c315t-76fac57be7a4fe717dcfcfbdc2657dddd41a525ef6c06351fa3c624b3c5ef6ff3</originalsourceid><addsrcrecordid>eNpdkE1LxDAQhoMorq5e_AES8CJCNR9N0xy1rB-w4kXPYZom0LVt1qRd8N-bZVcPzmWG4eFl5kHogpJbzji_qx5eMyoJJ-IAndBSiqwUih2mWcg8I1TwGTqNcUVIzilTx2jGFOGFLOUJWiw20E0wtn7A3uFow9TjqlrSEkPEgNd-tMPYQofr1vcQPm3AzgfsNxBaGLCBwdhwho4cdNGe7_scfTwu3qvnbPn29FLdLzPDqRgzWTgwQtZWQu6spLIxzri6MawQskmVUxBMWFcYUnBBHXBTsLzmZrtzjs_R9S53HfzXZOOo-zYa23UwWD9FTZVglEglSEKv_qErP4UhXZcolROihJKJutlRJvgYg3V6Hdr05remRG_l6iRX7-Qm-HIfOdW9bf7QX5v8B1GWc28</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1994009597</pqid></control><display><type>article</type><title>Evaluation of serum CCL18 as a potential biomarker for ovarian cancer</title><source>Alma/SFX Local Collection</source><creator>Yuan, Linjing ; Wan, Jianxin ; Huang, Chumei ; Liang, Jingjing ; Liu, Min ; Yue, Caifeng ; Li, Laisheng</creator><creatorcontrib>Yuan, Linjing ; Wan, Jianxin ; Huang, Chumei ; Liang, Jingjing ; Liu, Min ; Yue, Caifeng ; Li, Laisheng</creatorcontrib><description>Early detection and differentiation diagnosis of a pelvic mass (PM) is crucial in improving the prognosis of patients with epithelial ovarian cancer (EOC). C-C motif chemokine ligand 18 (CCL18) was reported as a chemokine-mediated tumor-related inflammation that can be detected in serum and may correlate with cancer patients' prognosis. We performed this study to investigate the relationship between CCL18 levels and clinical characteristics of EOC patients, and to explore their diagnostic and prognostic values. CCL18 serum concentrations were detected by ELISA in 187 patients with EOC, 126 patients with benign PMs, and 118 healthy controls. CCL18 serum levels were analyzed in the context of patients' clinicopathological information, and ROC analyses were performed to determine the effect of CCL18 on distinguishing benign and malignant PMs. The ability of CCL18 to serve as an EOC biomarker was compared with CA125. Further survival analyses were carried out to assess the prognostic value of CCL18 in EOC patients. Mean serum CCL18 levels were elevated in benign PM patients and were even higher in EOC patients than in healthy controls; furthermore, high CCL18 expression was associated with worse International Federation of Gynecology and Obstetrics (FIGO) staging and predicted a poorer survival of the patient. When compared with CA125, although the sensitivity and negative predictive values (NPV) of serum CCL18 were lower, its specificity and positive predictive values (PPV) were higher. Serum CCL18 was elevated in patients with EOC and could serve as a new tumor biomarker, which also predicted a poor survival of the patient.</description><identifier>ISSN: 1574-0153</identifier><identifier>EISSN: 1875-8592</identifier><identifier>DOI: 10.3233/CBM-170305</identifier><identifier>PMID: 29036787</identifier><language>eng</language><publisher>Netherlands: IOS Press BV</publisher><subject>Benign ; Biomarkers ; Cancer ; CCL18 protein ; Chemokines ; Diagnostic systems ; Enzyme-linked immunosorbent assay ; Gynecology ; Medical prognosis ; Obstetrics ; Ovarian cancer ; Patients ; Prognosis ; Serum levels ; Survival</subject><ispartof>Cancer biomarkers : section A of Disease markers, 2017-12, Vol.21 (1), p.97-104</ispartof><rights>Copyright IOS Press BV 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c315t-76fac57be7a4fe717dcfcfbdc2657dddd41a525ef6c06351fa3c624b3c5ef6ff3</citedby><cites>FETCH-LOGICAL-c315t-76fac57be7a4fe717dcfcfbdc2657dddd41a525ef6c06351fa3c624b3c5ef6ff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29036787$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yuan, Linjing</creatorcontrib><creatorcontrib>Wan, Jianxin</creatorcontrib><creatorcontrib>Huang, Chumei</creatorcontrib><creatorcontrib>Liang, Jingjing</creatorcontrib><creatorcontrib>Liu, Min</creatorcontrib><creatorcontrib>Yue, Caifeng</creatorcontrib><creatorcontrib>Li, Laisheng</creatorcontrib><title>Evaluation of serum CCL18 as a potential biomarker for ovarian cancer</title><title>Cancer biomarkers : section A of Disease markers</title><addtitle>Cancer Biomark</addtitle><description>Early detection and differentiation diagnosis of a pelvic mass (PM) is crucial in improving the prognosis of patients with epithelial ovarian cancer (EOC). C-C motif chemokine ligand 18 (CCL18) was reported as a chemokine-mediated tumor-related inflammation that can be detected in serum and may correlate with cancer patients' prognosis. We performed this study to investigate the relationship between CCL18 levels and clinical characteristics of EOC patients, and to explore their diagnostic and prognostic values. CCL18 serum concentrations were detected by ELISA in 187 patients with EOC, 126 patients with benign PMs, and 118 healthy controls. CCL18 serum levels were analyzed in the context of patients' clinicopathological information, and ROC analyses were performed to determine the effect of CCL18 on distinguishing benign and malignant PMs. The ability of CCL18 to serve as an EOC biomarker was compared with CA125. Further survival analyses were carried out to assess the prognostic value of CCL18 in EOC patients. Mean serum CCL18 levels were elevated in benign PM patients and were even higher in EOC patients than in healthy controls; furthermore, high CCL18 expression was associated with worse International Federation of Gynecology and Obstetrics (FIGO) staging and predicted a poorer survival of the patient. When compared with CA125, although the sensitivity and negative predictive values (NPV) of serum CCL18 were lower, its specificity and positive predictive values (PPV) were higher. Serum CCL18 was elevated in patients with EOC and could serve as a new tumor biomarker, which also predicted a poor survival of the patient.</description><subject>Benign</subject><subject>Biomarkers</subject><subject>Cancer</subject><subject>CCL18 protein</subject><subject>Chemokines</subject><subject>Diagnostic systems</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Gynecology</subject><subject>Medical prognosis</subject><subject>Obstetrics</subject><subject>Ovarian cancer</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Serum levels</subject><subject>Survival</subject><issn>1574-0153</issn><issn>1875-8592</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpdkE1LxDAQhoMorq5e_AES8CJCNR9N0xy1rB-w4kXPYZom0LVt1qRd8N-bZVcPzmWG4eFl5kHogpJbzji_qx5eMyoJJ-IAndBSiqwUih2mWcg8I1TwGTqNcUVIzilTx2jGFOGFLOUJWiw20E0wtn7A3uFow9TjqlrSEkPEgNd-tMPYQofr1vcQPm3AzgfsNxBaGLCBwdhwho4cdNGe7_scfTwu3qvnbPn29FLdLzPDqRgzWTgwQtZWQu6spLIxzri6MawQskmVUxBMWFcYUnBBHXBTsLzmZrtzjs_R9S53HfzXZOOo-zYa23UwWD9FTZVglEglSEKv_qErP4UhXZcolROihJKJutlRJvgYg3V6Hdr05remRG_l6iRX7-Qm-HIfOdW9bf7QX5v8B1GWc28</recordid><startdate>20171212</startdate><enddate>20171212</enddate><creator>Yuan, Linjing</creator><creator>Wan, Jianxin</creator><creator>Huang, Chumei</creator><creator>Liang, Jingjing</creator><creator>Liu, Min</creator><creator>Yue, Caifeng</creator><creator>Li, Laisheng</creator><general>IOS Press BV</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20171212</creationdate><title>Evaluation of serum CCL18 as a potential biomarker for ovarian cancer</title><author>Yuan, Linjing ; Wan, Jianxin ; Huang, Chumei ; Liang, Jingjing ; Liu, Min ; Yue, Caifeng ; Li, Laisheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c315t-76fac57be7a4fe717dcfcfbdc2657dddd41a525ef6c06351fa3c624b3c5ef6ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Benign</topic><topic>Biomarkers</topic><topic>Cancer</topic><topic>CCL18 protein</topic><topic>Chemokines</topic><topic>Diagnostic systems</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Gynecology</topic><topic>Medical prognosis</topic><topic>Obstetrics</topic><topic>Ovarian cancer</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Serum levels</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yuan, Linjing</creatorcontrib><creatorcontrib>Wan, Jianxin</creatorcontrib><creatorcontrib>Huang, Chumei</creatorcontrib><creatorcontrib>Liang, Jingjing</creatorcontrib><creatorcontrib>Liu, Min</creatorcontrib><creatorcontrib>Yue, Caifeng</creatorcontrib><creatorcontrib>Li, Laisheng</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer biomarkers : section A of Disease markers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yuan, Linjing</au><au>Wan, Jianxin</au><au>Huang, Chumei</au><au>Liang, Jingjing</au><au>Liu, Min</au><au>Yue, Caifeng</au><au>Li, Laisheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of serum CCL18 as a potential biomarker for ovarian cancer</atitle><jtitle>Cancer biomarkers : section A of Disease markers</jtitle><addtitle>Cancer Biomark</addtitle><date>2017-12-12</date><risdate>2017</risdate><volume>21</volume><issue>1</issue><spage>97</spage><epage>104</epage><pages>97-104</pages><issn>1574-0153</issn><eissn>1875-8592</eissn><abstract>Early detection and differentiation diagnosis of a pelvic mass (PM) is crucial in improving the prognosis of patients with epithelial ovarian cancer (EOC). C-C motif chemokine ligand 18 (CCL18) was reported as a chemokine-mediated tumor-related inflammation that can be detected in serum and may correlate with cancer patients' prognosis. We performed this study to investigate the relationship between CCL18 levels and clinical characteristics of EOC patients, and to explore their diagnostic and prognostic values. CCL18 serum concentrations were detected by ELISA in 187 patients with EOC, 126 patients with benign PMs, and 118 healthy controls. CCL18 serum levels were analyzed in the context of patients' clinicopathological information, and ROC analyses were performed to determine the effect of CCL18 on distinguishing benign and malignant PMs. The ability of CCL18 to serve as an EOC biomarker was compared with CA125. Further survival analyses were carried out to assess the prognostic value of CCL18 in EOC patients. Mean serum CCL18 levels were elevated in benign PM patients and were even higher in EOC patients than in healthy controls; furthermore, high CCL18 expression was associated with worse International Federation of Gynecology and Obstetrics (FIGO) staging and predicted a poorer survival of the patient. When compared with CA125, although the sensitivity and negative predictive values (NPV) of serum CCL18 were lower, its specificity and positive predictive values (PPV) were higher. Serum CCL18 was elevated in patients with EOC and could serve as a new tumor biomarker, which also predicted a poor survival of the patient.</abstract><cop>Netherlands</cop><pub>IOS Press BV</pub><pmid>29036787</pmid><doi>10.3233/CBM-170305</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1574-0153
ispartof Cancer biomarkers : section A of Disease markers, 2017-12, Vol.21 (1), p.97-104
issn 1574-0153
1875-8592
language eng
recordid cdi_proquest_miscellaneous_1952107950
source Alma/SFX Local Collection
subjects Benign
Biomarkers
Cancer
CCL18 protein
Chemokines
Diagnostic systems
Enzyme-linked immunosorbent assay
Gynecology
Medical prognosis
Obstetrics
Ovarian cancer
Patients
Prognosis
Serum levels
Survival
title Evaluation of serum CCL18 as a potential biomarker for ovarian cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T12%3A28%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20serum%20CCL18%20as%20a%20potential%20biomarker%20for%20ovarian%20cancer&rft.jtitle=Cancer%20biomarkers%20:%20section%20A%20of%20Disease%20markers&rft.au=Yuan,%20Linjing&rft.date=2017-12-12&rft.volume=21&rft.issue=1&rft.spage=97&rft.epage=104&rft.pages=97-104&rft.issn=1574-0153&rft.eissn=1875-8592&rft_id=info:doi/10.3233/CBM-170305&rft_dat=%3Cproquest_cross%3E1952107950%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1994009597&rft_id=info:pmid/29036787&rfr_iscdi=true